<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE- Â Â 
			Â </strong><br>Teva Women's Health, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Adenovirus Type 4 and Type 7 Vaccine, Live, Oral safely and effectively. See full prescribing information for Adenovirus Type 4 and Type 7 Vaccine, Live, Oral. <br><br>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral<br>Enteric Coated Tablets for Oral Administration<br>Initial U.S. Approval: 2011</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is approved for use in military populations 17 through 50 years of age.  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>A single vaccine dose is administered orally as two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. (<a href="#i4i_dosage_admin_id_a188aa2e-f0aa-4d1b-bf45-197bc37cd014">2</a>)</dd>
<dt>â€¢</dt>
<dd>Each of the two tablets should be swallowed whole. The tablets should not be chewed or crushed to avoid releasing the live adenovirus in the upper respiratory tract.</dd>
<dt>â€¢</dt>
<dd>Postpone administration in vaccinees with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">A single oral dose consists of one Adenovirus Type 4 tablet and one Adenovirus Type 7 tablet. (<a href="#i4i_dosage_form_strength_id_56b550de-847b-43be-b438-c6506f64a50f">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy (<a href="#i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a">4.1</a>, <a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>).</dd>
<dt>â€¢</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to any component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a Contraindication. (<a href="#i4i_section_id_79f5fe76-1507-4bee-93c5-73c11825bbba">4.2</a>, <a href="#i4i_description_id_c41662b3-079f-448f-b9df-791402fc9fbc">11</a>)</dd>
<dt>â€¢</dt>
<dd>Inability to swallow the tablets whole without chewing. (<a href="#i4i_section_id_7bd4e8f7-68d7-4262-957c-82b83b23ed28">4.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Safety and effectiveness have not been evaluated in persons with primary or acquired <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> states. (<a href="#i4i_section_id_ea3004c6-e9f1-449c-83da-c38b508c2198">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Vaccinees and individuals who come in close contact with vaccinees may be exposed to the vaccine viruses shed in the stool for up to 28 days. Proper personal hygiene can minimize this risk. (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>Vaccinees should exercise caution when in close contact with children less than 7 years of age, immunocompromised individuals and pregnant women during the 28 days following vaccination. (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common (â‰¥ 5%) systemic adverse reactions observed in clinical trials were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#i4i_adverse_effects_id_d743b511-af4b-4b3a-b989-614fc3c5b096">6</a>)<br><br> </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Teva Womenâ€™s Health at 1-866-626-6990 or VAERS at 1-800-822-7967 or <span class="Bold"><a href="http://www.vaers.hhs.gov">www.vaers.hhs.gov</a></span> </p>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Administration during pregnancy is contraindicated (<a href="#i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a">4.1</a>). </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 Indications and Usage</a></h1>
<h1><a href="#section-2" class="toc">2 Dosage and Administration</a></h1>
<h1><a href="#section-3" class="toc">3 Dosage Forms and Strengths</a></h1>
<h1><a href="#section-4" class="toc">4 Contraindications</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Pregnancy</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Inability to Swallow</a></h2>
<h1><a href="#section-5" class="toc">5 Warnings and Precautions</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Altered Immunocompetence </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Shedding and Transmission</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Human Serum Albumin</a></h2>
<h1><a href="#section-6" class="toc">6 Adverse Reactions</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 Drug Interactions</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Concomitant Vaccine Administration</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Immunosuppressive Therapies</a></h2>
<h1><a href="#section-8" class="toc">8 Use in Specific Populations</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 Description</a></h1>
<h1><a href="#section-10" class="toc">12 Clinical Pharmacology</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h1><a href="#section-11" class="toc">14 Clinical Studies</a></h1>
<h2><a href="#section-11.1" class="toc">14.1 Multicenter Safety and Efficacy Trial </a></h2>
<h1><a href="#section-12" class="toc">15 References</a></h1>
<h1><a href="#section-13" class="toc">16 How Supplied/Storage and Handling</a></h1>
<h1><a href="#section-14" class="toc">17 Patient Counseling Information</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_5d0b250f-ac07-4aaf-b3ec-65c9ae48a71b"></a><a name="section-1"></a><p></p>
<h1>1 Indications and Usage</h1>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, OralÂ  is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is approved for use in military populations 17 through 50 years of age. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a188aa2e-f0aa-4d1b-bf45-197bc37cd014"></a><a name="section-2"></a><p></p>
<h1>2 Dosage and Administration</h1>
<p class="First">A single vaccine dose is administered orally as two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. (<a href="#i4i_dosage_admin_id_a188aa2e-f0aa-4d1b-bf45-197bc37cd014">2</a>)</p>
<p>The tablets should be swallowed whole, without chewing, to avoid releasing the virus in the upper respiratory tract. <span class="Italics">[See Mechanism of Action (<a href="#i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f">12.1</a>)]</span></p>
<p>Postpone administration to individuals with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> because the effectiveness of the vaccine depends upon the multiplication of orally administered live adenovirus within the intestinal tract.<span class="Italics"> [See Mechanism of Action (<a href="#i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f">12.1</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_56b550de-847b-43be-b438-c6506f64a50f"></a><a name="section-3"></a><p></p>
<h1>3 Dosage Forms and Strengths</h1>
<p class="First">A single vaccine dose consists of two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_10048379-689d-47e1-86c6-3448aab6e55d"></a><a name="section-4"></a><p></p>
<h1>4 Contraindications</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Pregnancy</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should not be administered to pregnant females<span class="Italics"> [See Pregnancy (<a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>)]</span>. It is not known whether Adenovirus Type 4 and Type 7 Vaccine, Live, Oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Naturally occurring <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with adenoviruses has been associated with fetal harm. Pregnancy should be avoided for 6 weeks following receipt of vaccine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79f5fe76-1507-4bee-93c5-73c11825bbba"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to any component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a Contraindication. <span class="Italics">[See Description (<a href="#i4i_description_id_c41662b3-079f-448f-b9df-791402fc9fbc">11</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bd4e8f7-68d7-4262-957c-82b83b23ed28"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Inability to Swallow</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should not be administered to individuals incapable of swallowing each entire tablet, whole, without chewing. Chewing a tablet could expose the upper respiratory tract to live adenovirus leading to disease. <span class="Italics">[See Mechanism of Action (<a href="#i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f">12.1</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_27e2dcae-21d0-40bc-8700-8e0b10f03989"></a><a name="section-5"></a><p></p>
<h1>5 Warnings and Precautions</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea3004c6-e9f1-449c-83da-c38b508c2198"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Altered Immunocompetence </h2>
<p class="First">The safety and effectiveness of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral in immunocompromised individuals has not been evaluated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Shedding and Transmission</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains live viruses that are shed in the stool and can cause disease if transmitted. </p>
<p>People who come in close contact with those who were vaccinated, including other vaccinees, may be exposed to the virus present in the stool and may develop disease. <span class="Italics">[See Pharmacodynamics (<a href="#i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c">12.2</a>)]</span></p>
<p>Persons vaccinated with Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should exercise caution when in close contact with children less than 7 years of age and immunocompromised individuals such as those with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and cancer, or those receiving immunosuppressive therapy during the 28 day period of viral shedding following the vaccination. <span class="Italics">[See Use in Specific Populations (<a href="#i4i_nursing_mothers_id_0de4dd08-2bf9-41e5-b42e-381816b6d1c5">8.3</a>) and Pharmacodynamics (<a href="#i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c">12.2</a>)]</span></p>
<p>Vaccinees should exercise caution when in close contact with pregnant women during the 28 day period of shedding because fetal harm may result if pregnant women are exposed to adenovirus. <span class="Italics">[See Pregnancy (<a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>) and Pharmacodynamics (<a href="#i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c">12.2</a>)] </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4863e275-a6d3-4ab8-b79d-d7a6a6fe69f6"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Human Serum Albumin</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains albumin, a derivative of human blood. It is present at concentrations of &lt;0.3 mg/tablet. Based on effective donor screening, and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeld-Jakob disease (CJD) also is considered extremely remote. No cases of transmissions of viral diseases or CJD have ever been identified for human albumin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d743b511-af4b-4b3a-b989-614fc3c5b096"></a><a name="section-6"></a><p></p>
<h1>6 Adverse Reactions</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07bff764-4a14-453e-b8a8-d4184f0388d4"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a vaccine cannot be directly compared to the rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Multicenter Safety and Efficacy Trial </span></p>
<p>Safety of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral was evaluated in a multicenter, double-blind, randomized, placebo-controlled study that enrolled 3031 subjects who received vaccine and 1009 subjects who received placebo (lactose tablets). The study was conducted in healthy male (63%) and female (37%) active duty US Army and Navy military recruits during their basic training. The population had a mean age of 21 years, with an age range of 17 to 42 years. Race was 62% Caucasian, 18% African-American, 11% Hispanic, 3% Asian and 6% other. Subjects in both groups were administered other vaccines concomitantly with Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.Â  The specific vaccines that each subject received varied and were dependent on their immunization history.Â  The vaccines that were co-administered included <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Vaccine, Inactivated (Merck &amp; Co., Inc.), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Inactivated and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B (Recombinant) Vaccine (GlaxoSmithKline Biologicals), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Vaccine (Recombinant) (Merck &amp; Co., Inc.), Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant (Merck &amp; Co., Inc.), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> Vaccine, Live, Intranasal (MedImmune, LLC), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> Virus Vaccine (Sanofi Pasteur, Inc.), <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">Measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">Mumps</span>, and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">Rubella</span> Virus Vaccine Live (Merck &amp; Co., Inc.), Meningococcal (Groups A, C, Y and W-135) Polysaccharide, <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine (Sanofi Pasteur, Inc.), Meningococcal Polysaccharide Vaccine (Groups A, C, Y and W-135 Combined) (Sanofi Pasteur, Inc.), Poliovirus Vaccine Inactivated (Sanofi Pasteur, SA), <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine, Adsorbed (Sanofi Pasteur, Ltd.), <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine, Adsorbed (GlaxoSmithKline Biologicals), <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine (Sanofi Pasteur, SA), <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> Virus Vaccine Live (Merck &amp; Co., Inc.), <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">Yellow Fever</span> Vaccine (Sanofi Pasteur, Inc.).</p>
<p><span class="Bold">Serious Adverse Events</span></p>
<p>No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported during the multicenter safety and efficacy trial.</p>
<p>Serious adverse events in vaccine recipients included <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, febrile <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>. </p>
<p>Fifty-seven serious adverse events (SAEs) were reported during the six month study period with 39 reported between 0 and 56 days following treatment and 18 reported during the 56 to 180 day follow-up period. Thirty-five subjects (1.2%) who received vaccine (25 between 0 and 56 days from the date of vaccination, 10 during the 56 to 180 day follow-up period) and 12 subjects (1.2%) who received placebo (9 between 0 and 56 days from the date of treatment, 3 during the 56 to 180 day follow-up period) experienced at least one SAE. The SAEs occurring between Day 0 and Day 56 post-vaccination in the vaccine group, possibly associated with the receipt of the vaccine product as determined by the investigator, were as follows: one subject with <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (at 9 days post vaccination), one subject with febrile <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (at 4 days post vaccination, one subject with <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span> (at 23 days post vaccination), and one subject with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (at 23 days post vaccination); one SAE (<span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>) in the vaccine group occurred during the 56 to 180 day follow-up period and was determined to be possibly related to the vaccine product. A placebo recipient developed febrile acute respiratory disease where adenovirus Type 4 vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> was detected from posterior pharyngeal and tonsillar swabbing and characterized by serotyping and <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span> analysis. <span class="Italics">[See Warnings and Precautions: Shedding and Transmission (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)]</span></p>
<p>Overall, the percentage of subjects who experienced at least one adverse event during the 56 day study period was 91.2% in the Adenovirus Type 4 and Type 7 Vaccine, Live, Oral group compared to 93.9% in the placebo group. No subject in either treatment arm discontinued the study due to an adverse event. Adverse reactions were captured on a 2-Week Daily Diary (for a minimum of the first 780 subjects) or a 1-Week Daily Diary (for all remaining subjects) and were also reported at each study visit up to Day 56 after vaccination. Any reported AEs for Days 0-14 for the safety cohort and for Days 0-7 for the remaining subjects were defined as "solicited" because they were almost exclusively recorded directly by the subject from a pre-defined diary checklist. Although <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> was defined as â€œsolicitedâ€?, it was not on the pre-defined diary checklist. Any AEs reported spontaneously as part of the regular study visit or during a spontaneous visit to the clinic, for Days 15-56 for the safety cohort and Days 8-56 for the remaining subjects were designated as "non-solicited". </p>
<p><span class="Bold">Solicited Adverse Reactions</span></p>
<p>The following solicited adverse reactions were collected through daily diaries: stuffy nose, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> (within 14 days post enrollment for subjects in the initial safety cohort (n=878) and within 7 days post enrollment all subjects (n= 4040) for the rest of safety population). Those solicited adverse reactions reported by â‰¥ 5 % of subjects in either the vaccine or placebo treatment groups are presented in Table 1.</p>
<a name="_RefIDA576F835425F4DA2B30707BD91D25345"></a><table width="100%">
<caption><span>Table 1: Solicited Adverse Reactions, Days 0-7 for All Subjects and Days 8-14 for the Safety Cohort, Reported by â‰¥ 5% of Subjects in the Multicenter Safety and Efficacy Trial </span></caption>
<col width="33%">
<col width="12%">
<col width="13%">
<col width="9%">
<col width="13%">
<col width="5%">
<col width="6%">
<col width="4%">
<col width="6%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>MedDRA Preferred Term</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="4">
<p class="First"><span class="Bold"><span class="Underline">Adverse </span></span></p>
<p><span class="Bold"><span class="Underline">Reaction</span></span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
</td>
<td class="Botrule Lrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First">0-7 Days</p>
<p>N= 3031</p>
</td>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First">8-14 Days</p>
<p>N = 660</p>
</td>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First">0-7 Days</p>
<p>N= 1009</p>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First">8-14 Days</p>
<p>N = 218</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" colspan="2"></td>
<td class="Botrule Lrule" colspan="2"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">894</p></td>
<td class="Botrule Lrule" align="center"><p class="First">29.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">38</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">310</p></td>
<td class="Botrule Lrule" align="center"><p class="First">30.7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span> (Stuffy Nose)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">463</p></td>
<td class="Botrule Lrule" align="center"><p class="First">15.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">49</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">141</p></td>
<td class="Botrule Lrule" align="center"><p class="First">14.0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (<span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span>)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">391</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">72</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">124</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">59</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">130</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">412</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">137</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">310</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10.2</p></td>
<td class="Botrule Lrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">84</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> (temp â‰¥ 100.5Â°F) within 7 days, was reported to occur in 1.4% (42/3030) of vaccine recipients and 0.5% (5/961) of placebo recipients who were not diagnosed with ARD. During the 8-14 days post vaccination, rates of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> were 0.6% (4/659) and 1.1% (2/170) in vaccine and placebo recipients respectively.</p>
<p><span class="Bold">Non-Solicited Adverse Reactions</span></p>
<p>Non-solicited adverse reactions, that occurred Days 15-56 in the safety cohort and Days 8-56 for all remaining subjects, reported by â‰¥ 5 % of subjects in either the vaccine or placebo treatment groups are presented in Table 2.</p>
<a name="_RefIDE3748D9AB5DE4A42B544EE4C4A4F12FE"></a><table width="100%">
<caption><span>Table 2: Nonsolicited Adverse Reactions, Days 15-56 for the Safety Cohort and Days 8-56 for all Remaining Subjects, Reported by â‰¥ 5% of Subjects in the Multicenter Safety and Efficacy Trial </span></caption>
<col width="34%">
<col width="27%">
<col width="25%">
<col width="6%">
<col width="6%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>MedDRA Preferred Term</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"><span class="Bold">Adverse Reaction</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral </span><br><span class="Bold">N=3031</span></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">N=1009</span></p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td align="center"><p class="First">1135</p></td>
<td align="center"><p class="First">37.5</p></td>
<td align="center"><p class="First">397</p></td>
<td align="center"><p class="First">39.4</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td align="center"><p class="First">524</p></td>
<td align="center"><p class="First">17.3</p></td>
<td align="center"><p class="First">180</p></td>
<td align="center"><p class="First">17.8</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span></p></td>
<td align="center"><p class="First">443</p></td>
<td align="center"><p class="First">14.6</p></td>
<td align="center"><p class="First">157</p></td>
<td align="center"><p class="First">15.6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center"><p class="First">330</p></td>
<td align="center"><p class="First">10.9</p></td>
<td align="center"><p class="First">148</p></td>
<td align="center"><p class="First">14.7</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td align="center"><p class="First">257</p></td>
<td align="center"><p class="First">8.5</p></td>
<td align="center"><p class="First">91</p></td>
<td align="center"><p class="First">9.0</p></td>
</tr>
<tr>
<td><p class="First">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td align="center"><p class="First">253</p></td>
<td align="center"><p class="First">8.4</p></td>
<td align="center"><p class="First">73</p></td>
<td align="center"><p class="First">7.2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span></p></td>
<td align="center"><p class="First">229</p></td>
<td align="center"><p class="First">7.6</p></td>
<td align="center"><p class="First">73</p></td>
<td align="center"><p class="First">7.2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center"><p class="First">160</p></td>
<td align="center"><p class="First">5.3</p></td>
<td align="center"><p class="First">55</p></td>
<td align="center"><p class="First">5.5</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Botrule" align="center"><p class="First">77</p></td>
<td class="Botrule" align="center"><p class="First">2.5</p></td>
<td class="Botrule" align="center"><p class="First">51</p></td>
<td class="Botrule" align="center"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p>Less common (less than 5%) adverse reactions reported in the clinical trial in military recruits receiving Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, versus placebo, respectively included <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> (128 [4.22%] vs. 25 [2.48%]), <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span> (130 [4.29%] vs. 37 [3.67%]), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> greater than or equal to100.5 Â°F) (126 [4.16%] vs. 49 [4.86%]). </p>
<p><span class="Bold">Safety and Immunogenicity Trial </span></p>
<p>Five SAEs were reported among the 58 subjects in the safety and immunogenicity trial. Two SAEs occurred among the vaccine recipients: one case of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> reported on Day 33 of the follow-up period, and a report of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> occurring on Day 118 of follow-up period. Three SAEs were reported among placebo recipients: one case of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> on Day 10 and one case of <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span> reported on Day 14, and a right thigh <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> reported at Day 91.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_51fdf99c-ccf6-4c4f-a8e7-443ffe2762e4"></a><a name="section-7"></a><p></p>
<h1>7 Drug Interactions</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_635955b3-960d-4d77-970a-60d231b21312"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Concomitant Vaccine Administration</h2>
<p class="First">In clinical studies Adenovirus Type 4 and Type 7 Vaccine, Live, Oral was administered concurrently with other vaccines <span class="Italics">[See ADVERSE REACTIONS (<a href="#i4i_section_id_07bff764-4a14-453e-b8a8-d4184f0388d4">6.1</a>)]</span>. Data were not available to assess whether Adenovirus Type 4 and Type 7 Vaccine, Live, Oral interferes with the immune response to the other vaccines. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13fdb769-b7b2-4de4-89ad-49f64eb100f1"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Immunosuppressive Therapies</h2>
<p class="First">There are no data regarding the use of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral concomitantly with immunosuppressive therapies, e.g., irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses). <span class="Italics">[See Altered Immunocompetence (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_0e0cef21-7bc1-4749-ae48-129a6b8eb0db"></a><a name="section-8"></a><p></p>
<h1>8 Use in Specific Populations</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category</span>: Contraindication <span class="Italics">[See Contraindications (<a href="#i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a">4.1</a>)]</span></p>
<p>Five pregnancies were reported among women enrolled in the multicenter safety and efficacy trial of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral. Four of the subjects (3 vaccine recipients and 1 placebo recipient) were estimated to have conceived 2 to 13 days prior to vaccination. One subject (vaccine recipient) conceived approximately 21 weeks after vaccination. The deliveries to all five of the subjects were of healthy infants at estimated gestational ages between 36 and 40 weeks.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_334bb5c7-c8ac-4acd-bdcb-5c4ed407d770"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There is no information regarding the affect of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral on labor and delivery. Fecal shedding during delivery may result in vaccine virus transmission to the newborn infant.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0de4dd08-2bf9-41e5-b42e-381816b6d1c5"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is excreted in human milk. Because many viruses are excreted in human milk, caution should be exercised when Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is administered to a nursing woman. <span class="Italics">[See Warnings and Precautions (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_48b5d6a2-4431-4ab8-a767-70505bc8dd97"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral has not been evaluated in the age groups from birth through age 16.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_7352f2d1-f81c-465f-97fa-474bebda5c8a"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. There are no data to support use of this vaccine in geriatric (person â‰¥ 65 years) populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c41662b3-079f-448f-b9df-791402fc9fbc"></a><a name="section-9"></a><p></p>
<h1>11 Description</h1>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains viable, selected <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of human adenovirus Type 4 and human adenovirus Type 7 prepared in human-diploid fibroblast cell cultures (<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WI-38). Â The virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> have <span class="Bold">not </span>been attenuated. Â The cells are grown and the virus growth maintained in Dulbeccoâ€™s Modified Eagleâ€™s Medium, fetal bovine serum, and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. Â The virus is harvested, freed of particulate cellular material by filtration, formulated and dried by lyophilization. Â The dried virus material includes monosodium glutamate, sucrose, D-mannose, D-fructose, dextrose, human serum albumin, potassium phosphate and plasdone C. Â </p>
<p>The final vaccine is composed of two tablets (one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7) designed to pass intact through the stomach and release the live virus in the intestine. Â Each enteric-coated tablet contains an inner core tablet containing anhydrous lactose, microcrystalline cellulose, polacrilin potassium, magnesium stearate, and live adenovirus, either Type 4 or Type 7, at a potency of no fewer than 32,000 tissue-culture infective doses (4.5 log10 TCID<span class="Sub">50</span>) per tablet. Â The outer tablet layer contains microcrystalline cellulose, magnesium stearate, and anhydrous lactose, with an enteric coating consisting of cellulose acetate phthalate, alcohol, acetone, and castor oil. Â The Type 7 tablet also contains FD&amp;C Yellow #6 aluminum lake dye. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f7c72c68-11ee-4be0-ad11-839135131fe0"></a><a name="section-10"></a><p></p>
<h1>12 Clinical Pharmacology</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a live oral vaccine that replicates in the intestinal tract and induces immunity in persons with low or no pre-existing neutralizing antibodies. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold">Vaccine Virus Shedding</span></p>
<p>Fecal shedding of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> viruses was evaluated in a safety and immunogenicity study of 58 subjects (30 vaccine recipients and 28 placebo recipients) <span class="Italics">[See CLINICAL STUDIES (<a href="#i4i_clinical_studies_id_ecd7cc8a-7541-4ea1-a95a-2e1f2b882425">14</a>)]</span>. Stool or rectal swabs and throat swabs were collected on Day 0, 7, 14, 21, 28 and 56. Vaccine virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> were shed in the stool as early as day 7 following vaccination. Eight of 30 vaccine recipients (27%) tested positive at least once for Adenovirus Type 4 fecal shedding; 18 of 30 vaccine recipients (60%) tested positive for Adenovirus Type 7 fecal shedding. No adenovirus shedding was detectable in any subject by 28 days following vaccination. Vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> virus was not detected in the throat of any subject. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_ecd7cc8a-7541-4ea1-a95a-2e1f2b882425"></a><a name="section-11"></a><p></p>
<h1>14 Clinical Studies</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c0c1e68-5ce7-4c28-8adb-8ffb80ea62e2"></a><a name="section-11.1"></a><p></p>
<h2>14.1 Multicenter Safety and Efficacy Trial </h2>
<p class="First">A multicenter, double-blind, randomized, placebo-controlled study in US military recruits evaluated the safety and efficacy of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral to prevent wild Type 4 adenovirus-associated febrile acute respiratory disease (ARD) and to induce neutralizing antibody to Type 7 adenovirus. A seroconversion endpoint rather than prevention of clinical disease was used to assess efficacy of the Type 7 adenovirus vaccine component of this product as the incidence of febrile ARD due to Type 7 adenovirus was not anticipated to be high enough to permit a meaningful statistical assessment of the clinical effect of this vaccine component. Subjects were randomized to either the vaccine group or the placebo group in a 3:1 ratio. 4041 subjects were randomized, and 4040 subjects were analyzed. Females and males aged 17 or older and in good physical health were included in the study. No subjects were immunosuppressed or being treated with systemic immunosuppressive therapy. Baseline serology data is presented in Table 3. </p>
<a name="_RefID556650C0B3C54EAFBE069BBA790CEADF"></a><table width="100%">
<caption><span>Table 3: Baseline Serology in Multicenter Safety and Efficacy Trial </span></caption>
<col width="14%">
<col width="13%">
<col width="12%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Vaccine</span></p>
<p><span class="Bold">N=3031</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N=1009</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Total</span></p>
<p><span class="Bold">N=4040</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="Italics">Type 4 Titer</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">n (%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n (%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n (%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Negative*</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1906 (63%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">678 (67%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2584 (64%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Positive**</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1123 (37%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">331 (33%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1454 (36%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="Italics">Type 7 Titer</span></span></p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Negative*</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1159 (38%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">377 (37%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1536 (38%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Positive**</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1870 (62%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">632 (63%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2502 (62%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="4">
<p class="First">* Titer value was &lt;1:4 at visit 0.</p>
<p>** Titer value was â‰¥1:4 at visit 0.</p>
</td></tr>
</tbody>
</table>
<p><span class="Bold">Adenovirus Type 4 Efficacy and Immunogenicity </span></p>
<p><span class="Bold">Febrile Acute Respiratory Disease (ARD):</span> The results for the primary analysis of vaccine efficacy (VE) for adenovirus Type 4 and rate of wild Type 4 febrile ARD, are summarized in Table 4. Cases were defined as subjects with one or more clinical signs and symptoms of ARD (mild to severe: <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span> or <span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">rhonchi</span>), an oral temperature &gt; 100.5Â°F, and throat culture positive for wild Type 4 <span class="product-label-link" type="condition" conceptid="433413" conceptname="Disease due to Adenovirus">adenovirus infection</span>. Vaccine type Adenovirus was distinguished from wild type by a <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">Polymerase Chain Reaction</span> (PCR) assay.</p>
<a name="_RefIDFB860453DE8C435893F365E0CF605995"></a><table width="100%">
<caption><span>Table 4: Wild Adenovirus Type 4 Febrile ARD Cases (Day 0-56) In the Multicenter Safety and Efficacy Trial </span></caption>
<col width="37%">
<col width="24%">
<col width="20%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Adeno Type 4 ARD case</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Statistic </span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Vaccine</span></p>
<p><span class="Bold">N=3031</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N=1009</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Yes</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">48</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">VE (95% CI)<span class="Sup">Â§</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">99.3% (96.0%, 99.9%)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">*one additional subject met the case definition but had non-vaccine serotype (B3) adenovirus </p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="4"><p class="First">Â§Vaccine efficacy (VE) defined as: VE = 1 - RR, where RR = P(vaccine)/P(placebo) was the relative risk of ARD attack in subjects who received vaccine compared to placebo; 2-sided confidence interval, by using exact statistical methods. </p></td></tr>
</tbody>
</table>
<p><span class="Bold">Seroconversion Rate: </span>Adenovirus Type 4 seroconversion rate is presented in Table 5. Seroconversion is defined as the development of a Type 4 neutralizing antibody titer of greater or equal to 1:8 at Day 26 after vaccination in subjects whose baseline titer was less than 1:4. </p>
<a name="_RefID3EAC6DFD7530456F98F569FF3B045756"></a><table width="100%">
<caption><span>Table 5: Adenovirus Type 4 Seroconversion Rate (Day 26) in the Multicenter Safety and Efficacy Study </span></caption>
<col width="11%">
<col width="11%">
<col width="29%">
<col width="6%">
<col width="5%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live Oral</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First"><span class="Bold">Seroconversion</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Seroconversion </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center">
<p class="First"> %</p>
<p> (95% CI) </p>
</td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"> %</p>
<p>(95% CI)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">1841</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1739</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">94.5%</p>
<p>( 93.4%, 95.5% )</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">653</p></td>
<td class="Botrule Lrule" align="center"><p class="First">69</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">10.6 %</p>
<p>( 8.2%, 12.9% )</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Adenovirus Type 7 Immunogenicity</span></p>
<p><span class="Bold">Febrile Acute Respiratory Disease: </span>No Type 7 adenovirus-associated febrile or afebrile ARD cases were reported for either placebo or vaccine groups. This was expected given the estimated attack rate of adenovirus Type 7 in the military base training setting at the time of the study. Seroconversion was the primary evaluation of Type 7 effectiveness.</p>
<p><span class="Bold">Seroconversion Rate</span>: Results for the primary analysis of adenovirus Type 7 efficacy, seroconversion rate at Day 26, are summarized in Table 6. Seroconversion is defined as the development of a Type 7 neutralizing antibody titer of greater or equal to 1:8 at Day 26 after vaccination in subjects whose baseline titer was less than 1:4.</p>
<a name="_RefID3FD977033C1B439F84EA6442AA1D6162"></a><table width="100%">
<caption><span>Table 6: Adenovirus Type 7 Seroconversion Rate (Day 26) </span></caption>
<col width="11%">
<col width="11%">
<col width="30%">
<col width="6%">
<col width="5%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live Oral</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">Seroconversion </p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">Seroconversion </p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">% </span></p>
<p><span class="Bold">(95% CI)</span></p>
</td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">% </span></p>
<p><span class="Bold">(95% CI)</span> 0</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">1120</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1051</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">93.8% </p>
<p> ( 92.4%, 95.2% )</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">359</p></td>
<td class="Botrule Lrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">5.3% </p>
<p>( 3.0%, 7.6% )</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_8f588260-c3c7-4432-a479-9f0d9d58fe92"></a><a name="section-12"></a><p></p>
<h1>15 References</h1>
<dl>
<dt>1.</dt>
<dd>Van den Veyver et al. 1998. Detection of intrauterine <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> using the <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span>. Mol Genet Metab, 63: 85-95</dd>
<dt>2.</dt>
<dd>Calvin et al. 2000. Fatal intrauterine adenoviral endomyocarditis with aortic and pulmonary valve stenosis: diagnosis by <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span>. Hum Pathol. 31(11):1433-5</dd>
<dt>3.</dt>
<dd>Ranucci-Weiss et al. 1998. Intrauterine adenoviral <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> associated with fetal non-immune hydrops. Prenat. Diagn. 18(2):182-5</dd>
<dt>4.</dt>
<dd>Baschat et al., 2003. Is adenovirus a fetal pathogen? Am J Obstet Gynecol. 189(3):758-63.</dd>
<dt>5.</dt>
<dd>Fields Virology, Fifth Edition, 2007, p2409</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8b2c1184-7cbb-488a-b6ab-c6170144321a"></a><a name="section-13"></a><p></p>
<h1>16 How Supplied/Storage and Handling</h1>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Enteric Coated Tablets is packaged in a carton of two bottles of 100 tablets of each component of the vaccine:Â  </p>
<dl>
<dt>â€¢</dt>
<dd>Adenovirus Type 4 Component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral enteric coated tablet, a white to off-white, round, coated tablet with stylized b and a 4 imprinted on one side, for oral administration NDC 51285-174-02</dd>
<dt>â€¢</dt>
<dd>Adenovirus Type 7 Component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral enteric coated tablet, a light peach, round, coated tablet with stylized b and a 7 imprinted on one side, for oral administration NDC 51285-175-02</dd>
<dt>â€¢</dt>
<dd>Available as a single carton containing 1 x 100 tablets Adenovirus Type 4 Component and 1 x 100 tablets Adenovirus Type 7 Component NDC 51285-138-50</dd>
</dl>
<p>Store refrigerated between 2Â° and 8Â° C (35Â° and 46Â° F). Do not freeze. Keep bottle tightly closed and protect from moisture. Do not remove desiccant canister from bottle.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_023720ee-7b2c-42cc-9659-f59e8fc248dd"></a><a name="section-14"></a><p></p>
<h1>17 Patient Counseling Information</h1>
<p class="First">Swallow each tablet whole without chewing.</p>
<p>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains live virus that is shed in the stool for up to 28 days following vaccination and can cause disease if transmitted. It is given to individuals, undergoing intensive military training, who have limited contact with pregnant women, children under age seven and persons with compromised immune systems. To minimize the risk for transmitting and infecting others with the virus, take the following precautions during the 28 day period following vaccination:</p>
<dl>
<dt>â€¢</dt>
<dd>Observe proper personal hygiene, such as, frequent hand washing, especially following bowel movements.</dd>
<dt>â€¢</dt>
<dd>Caution is advised when in close contact with children less than 7 years of age, immunocompromised individuals (e.g., HIV infected, has cancer, or is receiving cancer treatments) and pregnant women because they may be more vulnerable to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> if exposed to the virus. </dd>
</dl>
<p>Inform women to contact their healthcare provider before receiving this vaccine if they are, or suspect they are, pregnant.</p>
<p>Inform women to avoid becoming pregnant following vaccination for at least 6 weeks after vaccination to prevent the fetus from being exposed to adenovirus. </p>
<p>If a pregnant woman receives Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, or a woman becomes pregnant within the 6 weeks following administration of vaccination, they should be enrolled in the Adenovirus Pregnancy Registry. <span class="Italics">[See Pregnancy (<a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>)]</span></p>
<p>If anyone has any questions or concerns regarding this vaccine, they should speak with their healthcare provider.</p>
<p><span class="Bold">Manufactured by Barr Labs, Inc.</span></p>
<p><span class="Bold">Distributed by Teva Pharmaceuticals USA, Inc., Sellersville, PA 18960</span></p>
<p>Iss. 4/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a2dcc086-49b9-4c67-a7c7-d82f13188069"></a><a name="section-15"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Adenovirus Type 4 Component - bottle label</h1>
<div class="Figure">
<a name="id1136"></a><img alt="Adenovirus Type 4 Component, bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7d0b43c-7250-4809-8a05-fcde5862f076&amp;name=image-01.jpg">
</div>
<p class="First">NDC 51285-174-02</p>
<p>Adenovirus Type 4 Component</p>
<p>Of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Enteric coated tablets,</p>
<p>For oral administration</p>
<p>NOT TO BE USED ALONE</p>
<p>Take with Adenovirus Type 7 Component</p>
<p>100 tablets</p>
<p>TEVA</p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5412b9c3-9010-4bdd-ac87-b1294e904d81"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Adenovirus Type 7 Component - bottle label</h1>
<div class="Figure">
<a name="id1149"></a><img alt="Adenovirus Type 7 Component, bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7d0b43c-7250-4809-8a05-fcde5862f076&amp;name=image-02.jpg">
</div>
<p class="First">NDC 51285-175-02</p>
<p>Adenovirus Type 7 Component</p>
<p>Of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Enteric coated tablets,</p>
<p>For oral administration</p>
<p>NOT TO BE USED ALONE</p>
<p>Take with Adenovirus Type 4 Component</p>
<p>100 tablets</p>
<p>TEVA</p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f3f3037a-4eb1-4e21-9e01-6797a5dd8449"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Adenovirus Type 4 and Type 7 Vaccine, Live, Oral - carton label</h1>
<div class="Figure">
<a name="id1162"></a><img alt="Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7d0b43c-7250-4809-8a05-fcde5862f076&amp;name=image-03.jpg">
</div>
<p class="First">NDC 51285-138-50</p>
<p>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral</p>
<p>Enteric Coated Tablets for Oral Administration</p>
<p>This vaccine product contains two (2) components.</p>
<p>Package Contains: One bottle of 100 tablets of Adenovirus Type 4 Component and One bottle of 100 tablets of Adenovirus Type 7 Component</p>
<p>One tablet of Adenovirus Type 4 Component and one tablet of Adenovirus Type 7 Component are to be taken at the same time.</p>
<p>Rx only</p>
<p>TEVA</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVEÂ 		
					</strong><br><span class="contentTableReg">adenovirus type 4 and type 7 vaccine, live kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-138</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-138-50</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">100Â </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">100Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADENOVIRUS TYPE 4 VACCINE, LIVEÂ 		
					</strong><br><span class="contentTableReg">adenovirus type 4 vaccine, live tablet, coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN ADENOVIRUS E SEROTYPE 4 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> CL-68578</strong> (HUMAN ADENOVIRUS E SEROTYPE 4 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> CL-68578) </td>
<td class="formItem">HUMAN ADENOVIRUS E SEROTYPE 4 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> CL-68578</td>
<td class="formItem">32000Â [TCID_50]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN HUMAN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FRUCTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNOSE, D-</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MONOSODIUM GLUTAMATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, UNSPECIFIED FORM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLACEFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125296</td>
<td class="formItem">09/16/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADENOVIRUS TYPE 7 VACCINE, LIVEÂ 		
					</strong><br><span class="contentTableReg">adenovirus type 7 vaccine, live tablet, coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN ADENOVIRUS B SEROTYPE 7 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 55142</strong> (HUMAN ADENOVIRUS B SEROTYPE 7 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 55142) </td>
<td class="formItem">HUMAN ADENOVIRUS B SEROTYPE 7 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 55142</td>
<td class="formItem">32000Â [TCID_50]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN HUMAN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FRUCTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNOSE, D-</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MONOSODIUM GLUTAMATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, UNSPECIFIED FORM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLACEFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (light peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b7</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125296</td>
<td class="formItem">09/16/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125296</td>
<td class="formItem">09/16/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Teva Women's Health, Inc.
							(017038951)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>40be36a7-4b70-4a2c-b74c-30206330509e</div>
<div>Set id: c7d0b43c-7250-4809-8a05-fcde5862f076</div>
<div>Version: 3</div>
<div>Effective Time: 20140623</div>
</div>
</div>Â <div class="DistributorName">Teva Women's Health, Inc.</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE- Â Â 
			Â </strong><br>Teva Women's Health, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Adenovirus Type 4 and Type 7 Vaccine, Live, Oral safely and effectively. See full prescribing information for Adenovirus Type 4 and Type 7 Vaccine, Live, Oral. <br><br>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral<br>Enteric Coated Tablets for Oral Administration<br>Initial U.S. Approval: 2011</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is approved for use in military populations 17 through 50 years of age.  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>A single vaccine dose is administered orally as two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. (<a href="#i4i_dosage_admin_id_a188aa2e-f0aa-4d1b-bf45-197bc37cd014">2</a>)</dd>
<dt>â€¢</dt>
<dd>Each of the two tablets should be swallowed whole. The tablets should not be chewed or crushed to avoid releasing the live adenovirus in the upper respiratory tract.</dd>
<dt>â€¢</dt>
<dd>Postpone administration in vaccinees with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">A single oral dose consists of one Adenovirus Type 4 tablet and one Adenovirus Type 7 tablet. (<a href="#i4i_dosage_form_strength_id_56b550de-847b-43be-b438-c6506f64a50f">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy (<a href="#i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a">4.1</a>, <a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>).</dd>
<dt>â€¢</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to any component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a Contraindication. (<a href="#i4i_section_id_79f5fe76-1507-4bee-93c5-73c11825bbba">4.2</a>, <a href="#i4i_description_id_c41662b3-079f-448f-b9df-791402fc9fbc">11</a>)</dd>
<dt>â€¢</dt>
<dd>Inability to swallow the tablets whole without chewing. (<a href="#i4i_section_id_7bd4e8f7-68d7-4262-957c-82b83b23ed28">4.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Safety and effectiveness have not been evaluated in persons with primary or acquired <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> states. (<a href="#i4i_section_id_ea3004c6-e9f1-449c-83da-c38b508c2198">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Vaccinees and individuals who come in close contact with vaccinees may be exposed to the vaccine viruses shed in the stool for up to 28 days. Proper personal hygiene can minimize this risk. (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>Vaccinees should exercise caution when in close contact with children less than 7 years of age, immunocompromised individuals and pregnant women during the 28 days following vaccination. (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common (â‰¥ 5%) systemic adverse reactions observed in clinical trials were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#i4i_adverse_effects_id_d743b511-af4b-4b3a-b989-614fc3c5b096">6</a>)<br><br> </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Teva Womenâ€™s Health at 1-866-626-6990 or VAERS at 1-800-822-7967 or <span class="Bold"><a href="http://www.vaers.hhs.gov">www.vaers.hhs.gov</a></span> </p>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Administration during pregnancy is contraindicated (<a href="#i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a">4.1</a>). </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 Indications and Usage</a></h1>
<h1><a href="#section-2" class="toc">2 Dosage and Administration</a></h1>
<h1><a href="#section-3" class="toc">3 Dosage Forms and Strengths</a></h1>
<h1><a href="#section-4" class="toc">4 Contraindications</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Pregnancy</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Inability to Swallow</a></h2>
<h1><a href="#section-5" class="toc">5 Warnings and Precautions</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Altered Immunocompetence </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Shedding and Transmission</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Human Serum Albumin</a></h2>
<h1><a href="#section-6" class="toc">6 Adverse Reactions</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 Drug Interactions</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Concomitant Vaccine Administration</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Immunosuppressive Therapies</a></h2>
<h1><a href="#section-8" class="toc">8 Use in Specific Populations</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 Description</a></h1>
<h1><a href="#section-10" class="toc">12 Clinical Pharmacology</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h1><a href="#section-11" class="toc">14 Clinical Studies</a></h1>
<h2><a href="#section-11.1" class="toc">14.1 Multicenter Safety and Efficacy Trial </a></h2>
<h1><a href="#section-12" class="toc">15 References</a></h1>
<h1><a href="#section-13" class="toc">16 How Supplied/Storage and Handling</a></h1>
<h1><a href="#section-14" class="toc">17 Patient Counseling Information</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_5d0b250f-ac07-4aaf-b3ec-65c9ae48a71b"></a><a name="section-1"></a><p></p>
<h1>1 Indications and Usage</h1>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, OralÂ  is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is approved for use in military populations 17 through 50 years of age. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a188aa2e-f0aa-4d1b-bf45-197bc37cd014"></a><a name="section-2"></a><p></p>
<h1>2 Dosage and Administration</h1>
<p class="First">A single vaccine dose is administered orally as two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. (<a href="#i4i_dosage_admin_id_a188aa2e-f0aa-4d1b-bf45-197bc37cd014">2</a>)</p>
<p>The tablets should be swallowed whole, without chewing, to avoid releasing the virus in the upper respiratory tract. <span class="Italics">[See Mechanism of Action (<a href="#i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f">12.1</a>)]</span></p>
<p>Postpone administration to individuals with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> because the effectiveness of the vaccine depends upon the multiplication of orally administered live adenovirus within the intestinal tract.<span class="Italics"> [See Mechanism of Action (<a href="#i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f">12.1</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_56b550de-847b-43be-b438-c6506f64a50f"></a><a name="section-3"></a><p></p>
<h1>3 Dosage Forms and Strengths</h1>
<p class="First">A single vaccine dose consists of two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_10048379-689d-47e1-86c6-3448aab6e55d"></a><a name="section-4"></a><p></p>
<h1>4 Contraindications</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Pregnancy</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should not be administered to pregnant females<span class="Italics"> [See Pregnancy (<a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>)]</span>. It is not known whether Adenovirus Type 4 and Type 7 Vaccine, Live, Oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Naturally occurring <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with adenoviruses has been associated with fetal harm. Pregnancy should be avoided for 6 weeks following receipt of vaccine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79f5fe76-1507-4bee-93c5-73c11825bbba"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to any component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a Contraindication. <span class="Italics">[See Description (<a href="#i4i_description_id_c41662b3-079f-448f-b9df-791402fc9fbc">11</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bd4e8f7-68d7-4262-957c-82b83b23ed28"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Inability to Swallow</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should not be administered to individuals incapable of swallowing each entire tablet, whole, without chewing. Chewing a tablet could expose the upper respiratory tract to live adenovirus leading to disease. <span class="Italics">[See Mechanism of Action (<a href="#i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f">12.1</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_27e2dcae-21d0-40bc-8700-8e0b10f03989"></a><a name="section-5"></a><p></p>
<h1>5 Warnings and Precautions</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea3004c6-e9f1-449c-83da-c38b508c2198"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Altered Immunocompetence </h2>
<p class="First">The safety and effectiveness of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral in immunocompromised individuals has not been evaluated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Shedding and Transmission</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains live viruses that are shed in the stool and can cause disease if transmitted. </p>
<p>People who come in close contact with those who were vaccinated, including other vaccinees, may be exposed to the virus present in the stool and may develop disease. <span class="Italics">[See Pharmacodynamics (<a href="#i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c">12.2</a>)]</span></p>
<p>Persons vaccinated with Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should exercise caution when in close contact with children less than 7 years of age and immunocompromised individuals such as those with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and cancer, or those receiving immunosuppressive therapy during the 28 day period of viral shedding following the vaccination. <span class="Italics">[See Use in Specific Populations (<a href="#i4i_nursing_mothers_id_0de4dd08-2bf9-41e5-b42e-381816b6d1c5">8.3</a>) and Pharmacodynamics (<a href="#i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c">12.2</a>)]</span></p>
<p>Vaccinees should exercise caution when in close contact with pregnant women during the 28 day period of shedding because fetal harm may result if pregnant women are exposed to adenovirus. <span class="Italics">[See Pregnancy (<a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>) and Pharmacodynamics (<a href="#i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c">12.2</a>)] </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4863e275-a6d3-4ab8-b79d-d7a6a6fe69f6"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Human Serum Albumin</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains albumin, a derivative of human blood. It is present at concentrations of &lt;0.3 mg/tablet. Based on effective donor screening, and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeld-Jakob disease (CJD) also is considered extremely remote. No cases of transmissions of viral diseases or CJD have ever been identified for human albumin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d743b511-af4b-4b3a-b989-614fc3c5b096"></a><a name="section-6"></a><p></p>
<h1>6 Adverse Reactions</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07bff764-4a14-453e-b8a8-d4184f0388d4"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a vaccine cannot be directly compared to the rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Multicenter Safety and Efficacy Trial </span></p>
<p>Safety of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral was evaluated in a multicenter, double-blind, randomized, placebo-controlled study that enrolled 3031 subjects who received vaccine and 1009 subjects who received placebo (lactose tablets). The study was conducted in healthy male (63%) and female (37%) active duty US Army and Navy military recruits during their basic training. The population had a mean age of 21 years, with an age range of 17 to 42 years. Race was 62% Caucasian, 18% African-American, 11% Hispanic, 3% Asian and 6% other. Subjects in both groups were administered other vaccines concomitantly with Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.Â  The specific vaccines that each subject received varied and were dependent on their immunization history.Â  The vaccines that were co-administered included <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Vaccine, Inactivated (Merck &amp; Co., Inc.), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Inactivated and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B (Recombinant) Vaccine (GlaxoSmithKline Biologicals), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Vaccine (Recombinant) (Merck &amp; Co., Inc.), Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant (Merck &amp; Co., Inc.), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> Vaccine, Live, Intranasal (MedImmune, LLC), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> Virus Vaccine (Sanofi Pasteur, Inc.), <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">Measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">Mumps</span>, and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">Rubella</span> Virus Vaccine Live (Merck &amp; Co., Inc.), Meningococcal (Groups A, C, Y and W-135) Polysaccharide, <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine (Sanofi Pasteur, Inc.), Meningococcal Polysaccharide Vaccine (Groups A, C, Y and W-135 Combined) (Sanofi Pasteur, Inc.), Poliovirus Vaccine Inactivated (Sanofi Pasteur, SA), <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine, Adsorbed (Sanofi Pasteur, Ltd.), <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine, Adsorbed (GlaxoSmithKline Biologicals), <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine (Sanofi Pasteur, SA), <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> Virus Vaccine Live (Merck &amp; Co., Inc.), <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">Yellow Fever</span> Vaccine (Sanofi Pasteur, Inc.).</p>
<p><span class="Bold">Serious Adverse Events</span></p>
<p>No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported during the multicenter safety and efficacy trial.</p>
<p>Serious adverse events in vaccine recipients included <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, febrile <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>. </p>
<p>Fifty-seven serious adverse events (SAEs) were reported during the six month study period with 39 reported between 0 and 56 days following treatment and 18 reported during the 56 to 180 day follow-up period. Thirty-five subjects (1.2%) who received vaccine (25 between 0 and 56 days from the date of vaccination, 10 during the 56 to 180 day follow-up period) and 12 subjects (1.2%) who received placebo (9 between 0 and 56 days from the date of treatment, 3 during the 56 to 180 day follow-up period) experienced at least one SAE. The SAEs occurring between Day 0 and Day 56 post-vaccination in the vaccine group, possibly associated with the receipt of the vaccine product as determined by the investigator, were as follows: one subject with <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (at 9 days post vaccination), one subject with febrile <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (at 4 days post vaccination, one subject with <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span> (at 23 days post vaccination), and one subject with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (at 23 days post vaccination); one SAE (<span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>) in the vaccine group occurred during the 56 to 180 day follow-up period and was determined to be possibly related to the vaccine product. A placebo recipient developed febrile acute respiratory disease where adenovirus Type 4 vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> was detected from posterior pharyngeal and tonsillar swabbing and characterized by serotyping and <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span> analysis. <span class="Italics">[See Warnings and Precautions: Shedding and Transmission (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)]</span></p>
<p>Overall, the percentage of subjects who experienced at least one adverse event during the 56 day study period was 91.2% in the Adenovirus Type 4 and Type 7 Vaccine, Live, Oral group compared to 93.9% in the placebo group. No subject in either treatment arm discontinued the study due to an adverse event. Adverse reactions were captured on a 2-Week Daily Diary (for a minimum of the first 780 subjects) or a 1-Week Daily Diary (for all remaining subjects) and were also reported at each study visit up to Day 56 after vaccination. Any reported AEs for Days 0-14 for the safety cohort and for Days 0-7 for the remaining subjects were defined as "solicited" because they were almost exclusively recorded directly by the subject from a pre-defined diary checklist. Although <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> was defined as â€œsolicitedâ€?, it was not on the pre-defined diary checklist. Any AEs reported spontaneously as part of the regular study visit or during a spontaneous visit to the clinic, for Days 15-56 for the safety cohort and Days 8-56 for the remaining subjects were designated as "non-solicited". </p>
<p><span class="Bold">Solicited Adverse Reactions</span></p>
<p>The following solicited adverse reactions were collected through daily diaries: stuffy nose, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> (within 14 days post enrollment for subjects in the initial safety cohort (n=878) and within 7 days post enrollment all subjects (n= 4040) for the rest of safety population). Those solicited adverse reactions reported by â‰¥ 5 % of subjects in either the vaccine or placebo treatment groups are presented in Table 1.</p>
<a name="_RefIDA576F835425F4DA2B30707BD91D25345"></a><table width="100%">
<caption><span>Table 1: Solicited Adverse Reactions, Days 0-7 for All Subjects and Days 8-14 for the Safety Cohort, Reported by â‰¥ 5% of Subjects in the Multicenter Safety and Efficacy Trial </span></caption>
<col width="33%">
<col width="12%">
<col width="13%">
<col width="9%">
<col width="13%">
<col width="5%">
<col width="6%">
<col width="4%">
<col width="6%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>MedDRA Preferred Term</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="4">
<p class="First"><span class="Bold"><span class="Underline">Adverse </span></span></p>
<p><span class="Bold"><span class="Underline">Reaction</span></span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
</td>
<td class="Botrule Lrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First">0-7 Days</p>
<p>N= 3031</p>
</td>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First">8-14 Days</p>
<p>N = 660</p>
</td>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First">0-7 Days</p>
<p>N= 1009</p>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First">8-14 Days</p>
<p>N = 218</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" colspan="2"></td>
<td class="Botrule Lrule" colspan="2"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">894</p></td>
<td class="Botrule Lrule" align="center"><p class="First">29.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">38</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">310</p></td>
<td class="Botrule Lrule" align="center"><p class="First">30.7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span> (Stuffy Nose)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">463</p></td>
<td class="Botrule Lrule" align="center"><p class="First">15.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">49</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">141</p></td>
<td class="Botrule Lrule" align="center"><p class="First">14.0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (<span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span>)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">391</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">72</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">124</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">375</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">59</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">130</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">412</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">137</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13.6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">310</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10.2</p></td>
<td class="Botrule Lrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">84</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> (temp â‰¥ 100.5Â°F) within 7 days, was reported to occur in 1.4% (42/3030) of vaccine recipients and 0.5% (5/961) of placebo recipients who were not diagnosed with ARD. During the 8-14 days post vaccination, rates of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> were 0.6% (4/659) and 1.1% (2/170) in vaccine and placebo recipients respectively.</p>
<p><span class="Bold">Non-Solicited Adverse Reactions</span></p>
<p>Non-solicited adverse reactions, that occurred Days 15-56 in the safety cohort and Days 8-56 for all remaining subjects, reported by â‰¥ 5 % of subjects in either the vaccine or placebo treatment groups are presented in Table 2.</p>
<a name="_RefIDE3748D9AB5DE4A42B544EE4C4A4F12FE"></a><table width="100%">
<caption><span>Table 2: Nonsolicited Adverse Reactions, Days 15-56 for the Safety Cohort and Days 8-56 for all Remaining Subjects, Reported by â‰¥ 5% of Subjects in the Multicenter Safety and Efficacy Trial </span></caption>
<col width="34%">
<col width="27%">
<col width="25%">
<col width="6%">
<col width="6%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>MedDRA Preferred Term</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"><span class="Bold">Adverse Reaction</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral </span><br><span class="Bold">N=3031</span></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">N=1009</span></p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td align="center"><p class="First">1135</p></td>
<td align="center"><p class="First">37.5</p></td>
<td align="center"><p class="First">397</p></td>
<td align="center"><p class="First">39.4</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td align="center"><p class="First">524</p></td>
<td align="center"><p class="First">17.3</p></td>
<td align="center"><p class="First">180</p></td>
<td align="center"><p class="First">17.8</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span></p></td>
<td align="center"><p class="First">443</p></td>
<td align="center"><p class="First">14.6</p></td>
<td align="center"><p class="First">157</p></td>
<td align="center"><p class="First">15.6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center"><p class="First">330</p></td>
<td align="center"><p class="First">10.9</p></td>
<td align="center"><p class="First">148</p></td>
<td align="center"><p class="First">14.7</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td align="center"><p class="First">257</p></td>
<td align="center"><p class="First">8.5</p></td>
<td align="center"><p class="First">91</p></td>
<td align="center"><p class="First">9.0</p></td>
</tr>
<tr>
<td><p class="First">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td align="center"><p class="First">253</p></td>
<td align="center"><p class="First">8.4</p></td>
<td align="center"><p class="First">73</p></td>
<td align="center"><p class="First">7.2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span></p></td>
<td align="center"><p class="First">229</p></td>
<td align="center"><p class="First">7.6</p></td>
<td align="center"><p class="First">73</p></td>
<td align="center"><p class="First">7.2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center"><p class="First">160</p></td>
<td align="center"><p class="First">5.3</p></td>
<td align="center"><p class="First">55</p></td>
<td align="center"><p class="First">5.5</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Botrule" align="center"><p class="First">77</p></td>
<td class="Botrule" align="center"><p class="First">2.5</p></td>
<td class="Botrule" align="center"><p class="First">51</p></td>
<td class="Botrule" align="center"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p>Less common (less than 5%) adverse reactions reported in the clinical trial in military recruits receiving Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, versus placebo, respectively included <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> (128 [4.22%] vs. 25 [2.48%]), <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span> (130 [4.29%] vs. 37 [3.67%]), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> greater than or equal to100.5 Â°F) (126 [4.16%] vs. 49 [4.86%]). </p>
<p><span class="Bold">Safety and Immunogenicity Trial </span></p>
<p>Five SAEs were reported among the 58 subjects in the safety and immunogenicity trial. Two SAEs occurred among the vaccine recipients: one case of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> reported on Day 33 of the follow-up period, and a report of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> occurring on Day 118 of follow-up period. Three SAEs were reported among placebo recipients: one case of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> on Day 10 and one case of <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span> reported on Day 14, and a right thigh <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> reported at Day 91.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_51fdf99c-ccf6-4c4f-a8e7-443ffe2762e4"></a><a name="section-7"></a><p></p>
<h1>7 Drug Interactions</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_635955b3-960d-4d77-970a-60d231b21312"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Concomitant Vaccine Administration</h2>
<p class="First">In clinical studies Adenovirus Type 4 and Type 7 Vaccine, Live, Oral was administered concurrently with other vaccines <span class="Italics">[See ADVERSE REACTIONS (<a href="#i4i_section_id_07bff764-4a14-453e-b8a8-d4184f0388d4">6.1</a>)]</span>. Data were not available to assess whether Adenovirus Type 4 and Type 7 Vaccine, Live, Oral interferes with the immune response to the other vaccines. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13fdb769-b7b2-4de4-89ad-49f64eb100f1"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Immunosuppressive Therapies</h2>
<p class="First">There are no data regarding the use of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral concomitantly with immunosuppressive therapies, e.g., irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses). <span class="Italics">[See Altered Immunocompetence (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_0e0cef21-7bc1-4749-ae48-129a6b8eb0db"></a><a name="section-8"></a><p></p>
<h1>8 Use in Specific Populations</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category</span>: Contraindication <span class="Italics">[See Contraindications (<a href="#i4i_section_id_a3d730ee-915d-4403-b3b7-6a628286937a">4.1</a>)]</span></p>
<p>Five pregnancies were reported among women enrolled in the multicenter safety and efficacy trial of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral. Four of the subjects (3 vaccine recipients and 1 placebo recipient) were estimated to have conceived 2 to 13 days prior to vaccination. One subject (vaccine recipient) conceived approximately 21 weeks after vaccination. The deliveries to all five of the subjects were of healthy infants at estimated gestational ages between 36 and 40 weeks.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_334bb5c7-c8ac-4acd-bdcb-5c4ed407d770"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There is no information regarding the affect of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral on labor and delivery. Fecal shedding during delivery may result in vaccine virus transmission to the newborn infant.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0de4dd08-2bf9-41e5-b42e-381816b6d1c5"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is excreted in human milk. Because many viruses are excreted in human milk, caution should be exercised when Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is administered to a nursing woman. <span class="Italics">[See Warnings and Precautions (<a href="#i4i_section_id_2258ce20-1280-4712-b102-7edce35350cb">5.2</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_48b5d6a2-4431-4ab8-a767-70505bc8dd97"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral has not been evaluated in the age groups from birth through age 16.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_7352f2d1-f81c-465f-97fa-474bebda5c8a"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. There are no data to support use of this vaccine in geriatric (person â‰¥ 65 years) populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c41662b3-079f-448f-b9df-791402fc9fbc"></a><a name="section-9"></a><p></p>
<h1>11 Description</h1>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains viable, selected <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of human adenovirus Type 4 and human adenovirus Type 7 prepared in human-diploid fibroblast cell cultures (<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WI-38). Â The virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> have <span class="Bold">not </span>been attenuated. Â The cells are grown and the virus growth maintained in Dulbeccoâ€™s Modified Eagleâ€™s Medium, fetal bovine serum, and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. Â The virus is harvested, freed of particulate cellular material by filtration, formulated and dried by lyophilization. Â The dried virus material includes monosodium glutamate, sucrose, D-mannose, D-fructose, dextrose, human serum albumin, potassium phosphate and plasdone C. Â </p>
<p>The final vaccine is composed of two tablets (one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7) designed to pass intact through the stomach and release the live virus in the intestine. Â Each enteric-coated tablet contains an inner core tablet containing anhydrous lactose, microcrystalline cellulose, polacrilin potassium, magnesium stearate, and live adenovirus, either Type 4 or Type 7, at a potency of no fewer than 32,000 tissue-culture infective doses (4.5 log10 TCID<span class="Sub">50</span>) per tablet. Â The outer tablet layer contains microcrystalline cellulose, magnesium stearate, and anhydrous lactose, with an enteric coating consisting of cellulose acetate phthalate, alcohol, acetone, and castor oil. Â The Type 7 tablet also contains FD&amp;C Yellow #6 aluminum lake dye. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f7c72c68-11ee-4be0-ad11-839135131fe0"></a><a name="section-10"></a><p></p>
<h1>12 Clinical Pharmacology</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c75068d3-1d66-46c5-b0ad-6b752cf2b84f"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a live oral vaccine that replicates in the intestinal tract and induces immunity in persons with low or no pre-existing neutralizing antibodies. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_d3c461b8-a2f3-40e0-a0f0-d0d06f60bd8c"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold">Vaccine Virus Shedding</span></p>
<p>Fecal shedding of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> viruses was evaluated in a safety and immunogenicity study of 58 subjects (30 vaccine recipients and 28 placebo recipients) <span class="Italics">[See CLINICAL STUDIES (<a href="#i4i_clinical_studies_id_ecd7cc8a-7541-4ea1-a95a-2e1f2b882425">14</a>)]</span>. Stool or rectal swabs and throat swabs were collected on Day 0, 7, 14, 21, 28 and 56. Vaccine virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> were shed in the stool as early as day 7 following vaccination. Eight of 30 vaccine recipients (27%) tested positive at least once for Adenovirus Type 4 fecal shedding; 18 of 30 vaccine recipients (60%) tested positive for Adenovirus Type 7 fecal shedding. No adenovirus shedding was detectable in any subject by 28 days following vaccination. Vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> virus was not detected in the throat of any subject. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_ecd7cc8a-7541-4ea1-a95a-2e1f2b882425"></a><a name="section-11"></a><p></p>
<h1>14 Clinical Studies</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c0c1e68-5ce7-4c28-8adb-8ffb80ea62e2"></a><a name="section-11.1"></a><p></p>
<h2>14.1 Multicenter Safety and Efficacy Trial </h2>
<p class="First">A multicenter, double-blind, randomized, placebo-controlled study in US military recruits evaluated the safety and efficacy of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral to prevent wild Type 4 adenovirus-associated febrile acute respiratory disease (ARD) and to induce neutralizing antibody to Type 7 adenovirus. A seroconversion endpoint rather than prevention of clinical disease was used to assess efficacy of the Type 7 adenovirus vaccine component of this product as the incidence of febrile ARD due to Type 7 adenovirus was not anticipated to be high enough to permit a meaningful statistical assessment of the clinical effect of this vaccine component. Subjects were randomized to either the vaccine group or the placebo group in a 3:1 ratio. 4041 subjects were randomized, and 4040 subjects were analyzed. Females and males aged 17 or older and in good physical health were included in the study. No subjects were immunosuppressed or being treated with systemic immunosuppressive therapy. Baseline serology data is presented in Table 3. </p>
<a name="_RefID556650C0B3C54EAFBE069BBA790CEADF"></a><table width="100%">
<caption><span>Table 3: Baseline Serology in Multicenter Safety and Efficacy Trial </span></caption>
<col width="14%">
<col width="13%">
<col width="12%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Vaccine</span></p>
<p><span class="Bold">N=3031</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N=1009</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Total</span></p>
<p><span class="Bold">N=4040</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="Italics">Type 4 Titer</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">n (%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n (%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n (%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Negative*</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1906 (63%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">678 (67%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2584 (64%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Positive**</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1123 (37%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">331 (33%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1454 (36%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold"><span class="Italics">Type 7 Titer</span></span></p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Negative*</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1159 (38%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">377 (37%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1536 (38%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Positive**</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1870 (62%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">632 (63%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2502 (62%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="4">
<p class="First">* Titer value was &lt;1:4 at visit 0.</p>
<p>** Titer value was â‰¥1:4 at visit 0.</p>
</td></tr>
</tbody>
</table>
<p><span class="Bold">Adenovirus Type 4 Efficacy and Immunogenicity </span></p>
<p><span class="Bold">Febrile Acute Respiratory Disease (ARD):</span> The results for the primary analysis of vaccine efficacy (VE) for adenovirus Type 4 and rate of wild Type 4 febrile ARD, are summarized in Table 4. Cases were defined as subjects with one or more clinical signs and symptoms of ARD (mild to severe: <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span> or <span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">rhonchi</span>), an oral temperature &gt; 100.5Â°F, and throat culture positive for wild Type 4 <span class="product-label-link" type="condition" conceptid="433413" conceptname="Disease due to Adenovirus">adenovirus infection</span>. Vaccine type Adenovirus was distinguished from wild type by a <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">Polymerase Chain Reaction</span> (PCR) assay.</p>
<a name="_RefIDFB860453DE8C435893F365E0CF605995"></a><table width="100%">
<caption><span>Table 4: Wild Adenovirus Type 4 Febrile ARD Cases (Day 0-56) In the Multicenter Safety and Efficacy Trial </span></caption>
<col width="37%">
<col width="24%">
<col width="20%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Adeno Type 4 ARD case</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Statistic </span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Vaccine</span></p>
<p><span class="Bold">N=3031</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N=1009</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Yes</p></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1*</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">48</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">VE (95% CI)<span class="Sup">Â§</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">99.3% (96.0%, 99.9%)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First">*one additional subject met the case definition but had non-vaccine serotype (B3) adenovirus </p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="4"><p class="First">Â§Vaccine efficacy (VE) defined as: VE = 1 - RR, where RR = P(vaccine)/P(placebo) was the relative risk of ARD attack in subjects who received vaccine compared to placebo; 2-sided confidence interval, by using exact statistical methods. </p></td></tr>
</tbody>
</table>
<p><span class="Bold">Seroconversion Rate: </span>Adenovirus Type 4 seroconversion rate is presented in Table 5. Seroconversion is defined as the development of a Type 4 neutralizing antibody titer of greater or equal to 1:8 at Day 26 after vaccination in subjects whose baseline titer was less than 1:4. </p>
<a name="_RefID3EAC6DFD7530456F98F569FF3B045756"></a><table width="100%">
<caption><span>Table 5: Adenovirus Type 4 Seroconversion Rate (Day 26) in the Multicenter Safety and Efficacy Study </span></caption>
<col width="11%">
<col width="11%">
<col width="29%">
<col width="6%">
<col width="5%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live Oral</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First"><span class="Bold">Seroconversion</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Seroconversion </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center">
<p class="First"> %</p>
<p> (95% CI) </p>
</td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"> %</p>
<p>(95% CI)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">1841</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1739</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">94.5%</p>
<p>( 93.4%, 95.5% )</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">653</p></td>
<td class="Botrule Lrule" align="center"><p class="First">69</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">10.6 %</p>
<p>( 8.2%, 12.9% )</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Adenovirus Type 7 Immunogenicity</span></p>
<p><span class="Bold">Febrile Acute Respiratory Disease: </span>No Type 7 adenovirus-associated febrile or afebrile ARD cases were reported for either placebo or vaccine groups. This was expected given the estimated attack rate of adenovirus Type 7 in the military base training setting at the time of the study. Seroconversion was the primary evaluation of Type 7 effectiveness.</p>
<p><span class="Bold">Seroconversion Rate</span>: Results for the primary analysis of adenovirus Type 7 efficacy, seroconversion rate at Day 26, are summarized in Table 6. Seroconversion is defined as the development of a Type 7 neutralizing antibody titer of greater or equal to 1:8 at Day 26 after vaccination in subjects whose baseline titer was less than 1:4.</p>
<a name="_RefID3FD977033C1B439F84EA6442AA1D6162"></a><table width="100%">
<caption><span>Table 6: Adenovirus Type 7 Seroconversion Rate (Day 26) </span></caption>
<col width="11%">
<col width="11%">
<col width="30%">
<col width="6%">
<col width="5%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Adenovirus Type 4 and Type 7 Vaccine, Live Oral</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">Seroconversion </p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">Seroconversion </p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">% </span></p>
<p><span class="Bold">(95% CI)</span></p>
</td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">n</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">% </span></p>
<p><span class="Bold">(95% CI)</span> 0</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">1120</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1051</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">93.8% </p>
<p> ( 92.4%, 95.2% )</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">359</p></td>
<td class="Botrule Lrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">5.3% </p>
<p>( 3.0%, 7.6% )</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_8f588260-c3c7-4432-a479-9f0d9d58fe92"></a><a name="section-12"></a><p></p>
<h1>15 References</h1>
<dl>
<dt>1.</dt>
<dd>Van den Veyver et al. 1998. Detection of intrauterine <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> using the <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span>. Mol Genet Metab, 63: 85-95</dd>
<dt>2.</dt>
<dd>Calvin et al. 2000. Fatal intrauterine adenoviral endomyocarditis with aortic and pulmonary valve stenosis: diagnosis by <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span>. Hum Pathol. 31(11):1433-5</dd>
<dt>3.</dt>
<dd>Ranucci-Weiss et al. 1998. Intrauterine adenoviral <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> associated with fetal non-immune hydrops. Prenat. Diagn. 18(2):182-5</dd>
<dt>4.</dt>
<dd>Baschat et al., 2003. Is adenovirus a fetal pathogen? Am J Obstet Gynecol. 189(3):758-63.</dd>
<dt>5.</dt>
<dd>Fields Virology, Fifth Edition, 2007, p2409</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8b2c1184-7cbb-488a-b6ab-c6170144321a"></a><a name="section-13"></a><p></p>
<h1>16 How Supplied/Storage and Handling</h1>
<p class="First">Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Enteric Coated Tablets is packaged in a carton of two bottles of 100 tablets of each component of the vaccine:Â  </p>
<dl>
<dt>â€¢</dt>
<dd>Adenovirus Type 4 Component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral enteric coated tablet, a white to off-white, round, coated tablet with stylized b and a 4 imprinted on one side, for oral administration NDC 51285-174-02</dd>
<dt>â€¢</dt>
<dd>Adenovirus Type 7 Component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral enteric coated tablet, a light peach, round, coated tablet with stylized b and a 7 imprinted on one side, for oral administration NDC 51285-175-02</dd>
<dt>â€¢</dt>
<dd>Available as a single carton containing 1 x 100 tablets Adenovirus Type 4 Component and 1 x 100 tablets Adenovirus Type 7 Component NDC 51285-138-50</dd>
</dl>
<p>Store refrigerated between 2Â° and 8Â° C (35Â° and 46Â° F). Do not freeze. Keep bottle tightly closed and protect from moisture. Do not remove desiccant canister from bottle.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_023720ee-7b2c-42cc-9659-f59e8fc248dd"></a><a name="section-14"></a><p></p>
<h1>17 Patient Counseling Information</h1>
<p class="First">Swallow each tablet whole without chewing.</p>
<p>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral contains live virus that is shed in the stool for up to 28 days following vaccination and can cause disease if transmitted. It is given to individuals, undergoing intensive military training, who have limited contact with pregnant women, children under age seven and persons with compromised immune systems. To minimize the risk for transmitting and infecting others with the virus, take the following precautions during the 28 day period following vaccination:</p>
<dl>
<dt>â€¢</dt>
<dd>Observe proper personal hygiene, such as, frequent hand washing, especially following bowel movements.</dd>
<dt>â€¢</dt>
<dd>Caution is advised when in close contact with children less than 7 years of age, immunocompromised individuals (e.g., HIV infected, has cancer, or is receiving cancer treatments) and pregnant women because they may be more vulnerable to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> if exposed to the virus. </dd>
</dl>
<p>Inform women to contact their healthcare provider before receiving this vaccine if they are, or suspect they are, pregnant.</p>
<p>Inform women to avoid becoming pregnant following vaccination for at least 6 weeks after vaccination to prevent the fetus from being exposed to adenovirus. </p>
<p>If a pregnant woman receives Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, or a woman becomes pregnant within the 6 weeks following administration of vaccination, they should be enrolled in the Adenovirus Pregnancy Registry. <span class="Italics">[See Pregnancy (<a href="#i4i_pregnancy_id_8fe16dbf-11ba-4c83-8249-4b99688bda8a">8.1</a>)]</span></p>
<p>If anyone has any questions or concerns regarding this vaccine, they should speak with their healthcare provider.</p>
<p><span class="Bold">Manufactured by Barr Labs, Inc.</span></p>
<p><span class="Bold">Distributed by Teva Pharmaceuticals USA, Inc., Sellersville, PA 18960</span></p>
<p>Iss. 4/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a2dcc086-49b9-4c67-a7c7-d82f13188069"></a><a name="section-15"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Adenovirus Type 4 Component - bottle label</h1>
<div class="Figure">
<a name="id1136"></a><img alt="Adenovirus Type 4 Component, bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7d0b43c-7250-4809-8a05-fcde5862f076&amp;name=image-01.jpg">
</div>
<p class="First">NDC 51285-174-02</p>
<p>Adenovirus Type 4 Component</p>
<p>Of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Enteric coated tablets,</p>
<p>For oral administration</p>
<p>NOT TO BE USED ALONE</p>
<p>Take with Adenovirus Type 7 Component</p>
<p>100 tablets</p>
<p>TEVA</p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5412b9c3-9010-4bdd-ac87-b1294e904d81"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Adenovirus Type 7 Component - bottle label</h1>
<div class="Figure">
<a name="id1149"></a><img alt="Adenovirus Type 7 Component, bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7d0b43c-7250-4809-8a05-fcde5862f076&amp;name=image-02.jpg">
</div>
<p class="First">NDC 51285-175-02</p>
<p>Adenovirus Type 7 Component</p>
<p>Of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Enteric coated tablets,</p>
<p>For oral administration</p>
<p>NOT TO BE USED ALONE</p>
<p>Take with Adenovirus Type 4 Component</p>
<p>100 tablets</p>
<p>TEVA</p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f3f3037a-4eb1-4e21-9e01-6797a5dd8449"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Adenovirus Type 4 and Type 7 Vaccine, Live, Oral - carton label</h1>
<div class="Figure">
<a name="id1162"></a><img alt="Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7d0b43c-7250-4809-8a05-fcde5862f076&amp;name=image-03.jpg">
</div>
<p class="First">NDC 51285-138-50</p>
<p>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral</p>
<p>Enteric Coated Tablets for Oral Administration</p>
<p>This vaccine product contains two (2) components.</p>
<p>Package Contains: One bottle of 100 tablets of Adenovirus Type 4 Component and One bottle of 100 tablets of Adenovirus Type 7 Component</p>
<p>One tablet of Adenovirus Type 4 Component and one tablet of Adenovirus Type 7 Component are to be taken at the same time.</p>
<p>Rx only</p>
<p>TEVA</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVEÂ 		
					</strong><br><span class="contentTableReg">adenovirus type 4 and type 7 vaccine, live kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-138</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-138-50</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">100Â </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">100Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADENOVIRUS TYPE 4 VACCINE, LIVEÂ 		
					</strong><br><span class="contentTableReg">adenovirus type 4 vaccine, live tablet, coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN ADENOVIRUS E SEROTYPE 4 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> CL-68578</strong> (HUMAN ADENOVIRUS E SEROTYPE 4 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> CL-68578) </td>
<td class="formItem">HUMAN ADENOVIRUS E SEROTYPE 4 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> CL-68578</td>
<td class="formItem">32000Â [TCID_50]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN HUMAN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FRUCTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNOSE, D-</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MONOSODIUM GLUTAMATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, UNSPECIFIED FORM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLACEFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125296</td>
<td class="formItem">09/16/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADENOVIRUS TYPE 7 VACCINE, LIVEÂ 		
					</strong><br><span class="contentTableReg">adenovirus type 7 vaccine, live tablet, coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN ADENOVIRUS B SEROTYPE 7 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 55142</strong> (HUMAN ADENOVIRUS B SEROTYPE 7 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 55142) </td>
<td class="formItem">HUMAN ADENOVIRUS B SEROTYPE 7 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 55142</td>
<td class="formItem">32000Â [TCID_50]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN HUMAN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FRUCTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNOSE, D-</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MONOSODIUM GLUTAMATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, UNSPECIFIED FORM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLACEFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (light peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b7</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125296</td>
<td class="formItem">09/16/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125296</td>
<td class="formItem">09/16/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Teva Women's Health, Inc.
							(017038951)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>40be36a7-4b70-4a2c-b74c-30206330509e</div>
<div>Set id: c7d0b43c-7250-4809-8a05-fcde5862f076</div>
<div>Version: 3</div>
<div>Effective Time: 20140623</div>
</div>
</div>Â <div class="DistributorName">Teva Women's Health, Inc.</div></p>
</body></html>
